Fluxion Biosciences Delivers First Commercial Shipments of IsoFlux™ System for Circulating Tumor Cell Analysis

Published: Jun 06, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluxion Biosciences, Inc. announced today that the first round of IsoFlux instruments has been delivered to customers around the world. Initially announced in November, the IsoFlux System is an automated instrument and microfluidic cartridge for high sensitivity enrichment of rare cells such as circulating tumor cells (CTCs), stem cells, and immune cells. The first 15 instrument placements included global pharma companies, emerging biotechs, and leading cancer research institutes.

Help employers find you! Check out all the jobs and post your resume.

Back to news